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Abstract
In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—
SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP), advances in the analy-
sis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular 
biomarkers of localized CRC are reviewed. Recently published information on the essential determination of KRAS, NRAS 
and BRAF mutations and the convenience of determining the amplification of human epidermal growth factor receptor 2 
(HER2), the expression of proteins in the DNA repair pathway and the study of NTRK fusions are also evaluated. From the 
pathological point of view, the importance of analysing the tumour budding and poorly differentiated clusters, and its prog-
nostic value in CRC is reviewed, as well as the impact of molecular lymph node analysis on lymph node staging in CRC. 
The incorporation of pan-genomic technologies, such as next-generation sequencing (NGS) and liquid biopsy in the clinical 
management of patients with CRC is also outlined. All these aspects are developed in this guide, which, like the previous 
one, will remain open to any necessary revision in the future.
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Introduction
During recent years, there have been advances related to 
the analysis of biomarkers with diagnostic, prognostic and 
therapeutic value in colorectal cancer (CRC), especially 
in advanced disease. Five years have passed since the last 
review of the consensus guide of the Spanish Society of 
Medical Oncology (Sociedad Española de Oncología 
Médica—SEOM) and the Spanish Society of Pathology 
(Sociedad Española de Anatomía Patológica—SEAP) [1], 
and it is important to update it to incorporate the advances 
that facilitate the administration of precision therapies to 
these patients.
In addition, this review examines the novelty of heredi-
tary CRC susceptibility markers and the molecular biomark-
ers of localized CRC. Recently published information on the 
essential determination of KRAS, NRAS and BRAF muta-
tions is also evaluated [2], as well as the convenience of 
determining other biomarkers, such as the amplification of 
the epidermal growth factor receptor (HER2), the expres-
sion of proteins in the DNA repair pathway and the study of 
NTRK fusions [2].
From a pathology point of view, new data have been pub-
lished with a high degree of evidence regarding the diag-
nostic and prognostic value of some biomarkers that will be 
detailed in this review. One example is the incorporation into 
pathology diagnostic protocols the analysis of the tumour 
budding (TB), defined as the presence of isolated tumour 
cells or small groups of less than five tumour cells at the 
invasive tumour front, or the poorly differentiated clusters 
(PDC), defined as groups of five or more tumour cells at 
the invasive front of the stroma of the CRC which does not 
form glandular structures. Both, TB and PDC are prognostic 
factors in CRC [3, 4].
Another important pathological aspect is the introduc-
tion of new molecular assays for the analysis of lymph 
nodes extracted from surgical specimens of CRC. The 
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pooling-OSNA® (one-step nucleic acid amplification) 
method, based on the RT-LAMP (reverse transcription 
loop-mediated isothermal amplification) of cytokeratin 19 
(CK19) mRNA for the detection of lymph node metastases, 
surpassing the current performance of conventional morpho-
logical analysis with H&E. Molecular lymph node staging 
is relevant, especially in the early stages of the disease [5].
Finally, this review evaluates the future incorporation 
of new pan-genomic technologies, such as next-generation 
sequencing (NGS) and liquid biopsy for the clinical manage-
ment of patients with CRC. All these aspects are developed 
in this guide, which, like the previous one, will remain open 
to any necessary revision in the future.
Clinical aspects
Molecular markers of hereditary CRC susceptibility
Of all CRC cases diagnosed each year, 25% present some 
characteristic indicating hereditary cancer susceptibility. Of 
these, 5% correspond to Lynch syndrome, 1% to polyposis 
and the rest to what could be called ‘family aggregations’.
The identification of these clinical pictures has a high 
impact on the prevention of CRC, given that the identifica-
tion of incipient neoplastic lesions leads to cure rates of up 
to 90% and affects comorbidities, quality of life and health 
efficiency.
Lynch syndrome
The identification of this type of syndrome is based on the 
Amsterdam I and II criteria [6, 7], which are exclusively 
clinical. When a family complies, genetic testing should be 
offered to identify the presence of germline mutations in 
DNA repair genes (mismatch repair [MMR] genes), such as 
MLH1, MSH2, MSH6 and PMS2. This genetic study should 
always be accompanied by adequate genetic counselling.
The algorithm for the identification of these mutations 
is well described and accepted by different scientific socie-
ties (Fig. 1). Initial screening is performed by identifying 
the lack of expression of the corresponding proteins of the 
genes involved in CRC and/or endometrium or by analysing 
microsatellite instability [MSI]. Any of these techniques is 
fully accepted today, and each has its specificities. In the 
case that any of these alterations exist, and once it has been 
Fig. 1  Performance algorithm to detect Lynch syndrome. aAssess 
at the individual level. bWhen there is no available tumour, but the 
Amsterdam criteria are met and the implications for the family are 
important, the option of conducting a study of germline mutations in 
MMR genes should be evaluated. cWhen there are no living or avail-
able affects, the germinal study should be evaluated in a healthy sub-
ject, as long as the impact on family management is important. dIn 
the event that the lack of expression is in MLH1, promoter methyla-
tion analysis and B6A6 V600E mutation should be performed. IHC 
immunohistochemistry, MMR mismatch repair genes, MSI microsat-
ellite instability
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ruled out that it is due to an exclusively somatic alteration, 
the germinal study of the MMR genes should be performed.
Notably, at present, this type of study is being performed 
in any patient with CRC. This measure is justified not only 
by the preventive implications for the patient and their fami-
lies but also because it helps to decide whether to administer 
adjuvant therapy in patients in whom the indication of such 
treatment is doubtful [8].
Polyopsis syndromes
The main characteristic of polyposis syndromes, which usu-
ally affect the younger population, is the development of a 
large number of polyps along the digestive tract, with differ-
ent histologies and associated with other systemic lesions, 
with no histological markers to identify them.
If a person and/or their family have a polyposis syndrome, 
genetic counselling should be offered, and a germinal study 
of MMR genes should be carried out according to the clini-
cal picture.
Taking into account this information, this panel of experts 
recommends the following:
• Perform MSI and/or immunohistochemistry (IHC) analy-
sis for all patients diagnosed with CRC; and
• Continue with the germinal study of MMR genes in 
patients in which MSI is observed and/or loss of expres-
sion of repair proteins, provided that an exclusively 
somatic origin has been ruled out.
Molecular markers of localized CRC 
The use of adjuvant chemotherapy in patients with stage II 
CRC is controversial and is only recommended if at least one 
validated risk factor is observed. Among the clinical, patho-
logical and molecular markers that have been correlated with 
progression-free survival (PFS) and overall survival (OS), 
only the evaluation of MSI versus stable microsatellites 
(MSs), T3 versus T4 and the number of lymph nodes ana-
lysed (≥ 12–14 versus < 12–14) have been validated repeat-
edly in prospective randomized clinical trials [9].
However, in patients with stage III CRC, the prognostic 
value of MSI is attenuated and is not observed in several 
large prospective cohort studies. The determination of altera-
tions in RAS and BRAF has been shown to have prognostic 
value in recent randomized cohort studies but currently has 
no clinical utility [10].
Several multigenic tests have been developed with a com-
mercial vision, but their overlap is low, and their clinical 
application is not guaranteed [11]. These tests have focused 
on patients with stage II CRC, in whom the evidence for 
administering adjuvant chemotherapy is conflictive, with 
the aim of selecting patients with higher risk and, therefore, 
who may benefit more from chemotherapy. Only two tests, 
Oncotype  DX® and  GeneFx® Colon [12], have been vali-
dated in cohorts of prospective and randomized patients by 
multivariate analysis in formalin-fixed paraffin-embedded 
(FFPE) tumour samples. Oncotype  DX® is the genetic 
test with the most evidence and has been developed as a 
real-time polymerase chain reaction (RT-PCR) multigenic 
quantitative test. Its prognostic value has been observed in 
four independent prospective clinical trials that randomized 
patients with stage II CRC, observing hazard ratios (HR) 
between 1.43 and 1.68 [13–16]. It is important to note that 
Oncotype  DX® maintains its prognostic value when other 
clinically relevant prognostic factors, such as T4 or MSI, are 
included in the multivariate analysis. However, its clinical 
utility is not guaranteed due to the lack of predictive value 
of the benefit of chemotherapy, as well as the small, but 
significant, prognostic differentiation between low, interme-
diate and high risk.
In this context, Immunoscore® has recently emerged 
as an alternative prognostic biomarker. It has been devel-
oped as a quantitative measure of the presence of CD3+ /
CD8+ lymphocytes that have invaded a tumour. Both its 
internal validity and its external clinical validation have been 
demonstrated in long series of patients with stages II and III 
CRC through multivariate analysis, including when other 
factors, such as clinical stage and MSI status, were included 
in the multivariate analysis.[17]. However, the predictive 
value of the benefit of chemotherapy is uncertain and lacks 
independent evidence that demonstrates its prognostic value 
in stage II CRC, which is only observed when combined 
with known clinicopathological markers and MSI status.
More promising is the analysis of circulating tumour 
DNA (ctDNA), through which minimal residual disease can 
be detected with high prognostic value. If this is validated in 
the studies of clinical utility that are being carried out, these 
biomarkers may be the most robust in the near future [18]. 
Lastly, lack of CDX2 expression confers poor prognosis in 
stage 2 and may also predict benefit from adjuvant chemo-
therapy, but this must be confirmed in larger prospective 
randomized series [19].
Essential molecular markers of advanced CRC 
CRC is a disease characterized by its high heterogeneity, 
a product of genomic instability and its interaction with 
multiple exogenous factors that influence carcinogenesis 
(diet, lifestyle, microbiome, etc.) and that constitutes the 
exposome. This genomic heterogeneity translates into dif-
ferent models of carcinogenesis and, ultimately, different 
phenotypes. Some of these genomic alterations can directly 
influence the selection of treatments; therefore, it is standard 
practice to determine the mutational state of multiple genes, 
including the determination of the extended RAS mutation, 
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the BRAF V600E mutation and the MSI status, which is 
usually performed by IHC staining for MLH1, MSH2, MSH6 
and PMS2.
RAS mutations
The main biomarker of clinical utility in metastatic 
CRC is the mutational state of genes in the RAS family 
(KRAS/NRAS/HRAS). Mutations are present in approxi-
mately 50% of cases, the most frequent being those that 
occur in codons 12 and 13 of exon 2 and that condition a 
state of cellular expansion.
RAS mutations are a predictor of the absence of response 
to treatment with epidermal growth factor receptor (EGFR) 
inhibitors, such as cetuximab and panitumumab. In the 
CRYSTAL study, the addition of cetuximab to the regimen 
with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) 
showed an increase in the response rate (57% versus 40%; 
p < 0.001) and median OS (23.5 versus 20.0 months; HR 
0.796; p = 0.0093) in patients with tumours without KRAS 
mutations [20]. However, in patients with tumours with 
KRAS mutations, a 4% decrease in the response rate was 
evidenced, and there were no significant differences in terms 
of OS [20]. Similar findings were found when analysing the 
OPUS trial, in which the chemotherapy regimen was folinic 
acid, 5-fluorouracil and oxaliplatin (FOLFOX) with cetuxi-
mab, and in the PRIME trial, in which FOLFOX was com-
bined with panitumumab [21, 22]. Taking into account these 
data [23], guidelines from the American Society of Clini-
cal Oncology (ASCO), the European Society for Medical 
Oncology (ESMO) and the National Comprehensive Cancer 
Network (NCCN) recommend the extended determination of 
RAS mutations before the administration of EGFR inhibitors 
[8, 24, 25]. The RAS analysis should include HRAS, KRAS 
and NRAS, exons 2 (codons 12 and 13), 3 (codons 59 and 
61) and 4 (codons 117 and 146) [8, 24, 25].
BRAF mutations
The most frequent BRAF mutation is the substitution of 
glutamic acid for valine in codon V600E, which produces 
constitutive activation of the MAPK pathway. This muta-
tion occurs in 8–10% of patients with metastatic CRC and 
excludes the RAS mutation [26]. It is more common in 
women, usually appears in more advanced stages and has 
been associated with tumours of the right colon, poorly dif-
ferentiated, with mucinous histology and with MSI. Addi-
tionally, it seems that BRAF mutations lead to the develop-
ment of more peritoneal metastases and less disease limited 
to the liver or lung.
Regarding the prognostic role of BRAF, it seems that 
mutation is a negative prognostic factor, although its asso-
ciation with MSI has to be taken into account. A joint 
analysis of four phase III clinical trials of first-line treat-
ment in patients with metastatic CRC evaluated the possible 
prognostic value of BRAF [27]. In a total of 3063 patients, of 
whom 8.2% had a BRAF mutation, the OS was 11.4 months, 
and the PFS was 6.2 months, compared to 17.2 months and 
7.7 months, respectively, that were observed in patients 
without BRAF mutations (p < 0.001). This same study 
analysed the possible prognostic value of MSI, and it was 
observed that the OS for patients with MSI of high instabil-
ity (MSI-H) was 13.6 months, while in patients with MSs, 
it was 16.8 months (p = 0.001). When the BRAF and MSI 
statuses were analysed, there were no differences in terms 
of PFS or OS in the MSI-H population regardless of BRAF 
status, but in the MSs population with mutated BRAF, a sig-
nificant decrease in OS and PFS was observed. These data 
support the negative prognostic value of BRAF mutations.
Recent data support the predictive value of BRAF muta-
tions [28]. Phase III BEACON Colorectal Cancer Study 
enrolled 665 patients with BRAF V600E across three 
cohorts, including the triplet regimen of encorafenib, bini-
metinib and cetuximab; the doublet regimen of encorafenib 
and cetuximab; and a control cohort where patients could 
receive either cetuximab and irinotecan or cetuximab with 
FOLFIRI. At the time of the interim analysis, the median 
duration of follow-up was 7.8 months. The median OS 
was 5.4 months, 8.4 months and 9.0 months for the con-
trol group, the doublet regimen arm, and the triplet regi-
men arm, respectively. Comparing the results obtained in 
the triplet regimen arm with the control group, HR was 
0.52 (p < 0.001). An independent central review committee 
assessed the response rate in this analysis for the first 331 
randomized patients. The response rate in the control arm 
was 2% compared with 20% in the doublet regimen arm and 
26% in the triplet regimen arm (control arm versus triplet 
regimen arm; p < 0.001).
MSI
Mutations in the MLH1, MSH2, MSH6 and PMS2 genes are 
related to poor MMR as well as MSI. They appear in 15% of 
stage II and III tumours but in only 4% of stage IV tumours. 
In stages II–III, MSI is related to a better prognosis, and 
specifically in stage II, the better prognosis occurs in the 
absence of benefits from adjuvant treatment with fluoropy-
rimidines. However, MSI in stage IV is associated with an 
unfavourable prognosis, most likely due to its association 
with BRAF mutations.
Two recent studies show that the alteration of MMR 
may have a predictive role in response to immunotherapy; 
therefore, the NCCN recommends its determination in all 
patients with metastatic CRC [29, 30]. The Food and Drug 
Administration (FDA) has approved the use of nivolumab 
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and pembrolizumab in patients with MMR-deficient and 
MSI-H metastatic CRC.
Recommended molecular markers of advanced CRC 
HER2 is overexpressed in a small proportion of CRC. The 
Cancer Genome Atlas (TCGA) project identified somatic 
amplifications or mutations of HER2 in 7% of CRC cases 
and in 5% of the non-hypermutated CRC subgroup (4% 
amplification, 3% mutation and 1% both), being more fre-
quent in native RAS tumours (8%) [31]. An analysis of 3256 
patients with CRC from different clinical trials (QUASAR, 
FOCUS and PICCOLO) confirmed a higher incidence 
of HER2-positive CRC in native KRAS/BRAF tumours 
and advanced stages [32]. Some studies indicate that the 
amplification of HER2 is more frequent in distal tumours 
(PETACC-3 and HERACLES-A), but others have not con-
firmed that observation (PETACC-8) [33]. Its association 
with survival is also controversial [32, 33].
Protein overexpression and gene amplification are eas-
ily detectable by IHC or fluorescent in situ hybridization 
(FISH), respectively. The criteria developed and validated 
in the HERACLES programme defined HER2-positive 
tumours as tumours with an IHC staining intensity of 3+ in 
more than 50% of cells or a staining intensity of 2+ with a 
HER2:CEP ratio (chromosome enumeration probe) greater 
than 2 per FISH in more than 50% of the cells [34]. Amplifi-
cation of HER2 is involved in innate and acquired resistance 
to anti-EGFR drugs [33]. The dual inhibition of HER2 (lapa-
tinib and trastuzumab or pertuzumab), but not the simple 
block, is capable of inducing durable responses in patient-
derived xenograft (PDX) models of native RAS/BRAF/PI3K 
cetuximab-resistant CRC [33]. Consistent with this, the 
HERACLES-A trial documented a response rate of 30% 
in 27 patients with native KRAS CRC, positive HER2, and 
anti-EGFR resistance treated with lapatinib and trastuzumab 
[35]. Similarly, in the MyPathway Phase II trial, a response 
rate of 38% was observed in 37 patients with HER2-positive 
metastatic CRC treated with trastuzumab and pertuzumab 
[36]. Other strategies being explored are anti-HER2 mono-
clonal antibody–drug conjugates, such as trastuzumab-
emtansine (HERACLES-B and RESCUE assays), and tras-
tuzumab-deruxtecan, at a 25% response rate documented in 
a phase I study in 12 patients with HER2-positive CRC [37]. 
The determination of HER2 may, therefore, be of clinical 
utility and could be justified at least in native RAS tumours 
resistant to anti-EGFR treatment.
The constitutive activation of different kinases as a con-
sequence of gene translocations plays an essential role in 
the tumourigenesis of multiple neoplasias, including a 
subgroup of neoplasias of the colon and rectum, and their 
pharmacological inhibition constitutes one of the greatest 
therapeutic successes in the field of precision oncology. In 
a recent series, in which 18,407 tumour samples and 513 
ctDNA samples from CRC patients were characterized by 
massive sequencing, genetic rearrangements of potentially 
treatable kinases were identified in 126 tumours (0.68%) and 
seven ctDNA samples (1.36%) [38]. The most frequently 
identified fusions in this series involved the RET (0.15%), 
BRAF (0.12%), NTRK1 (0.14%) and ALK (0.09%) genes. 
Ninety percent of the tumours with these gene rearrange-
ments were native KRAS, with a high proportion of MSI-
H: 86.4%, 45.5% and 14.3% of the tumours with NTRK1, 
RET and ALK fusions, respectively. The presence of MSI or 
the absence of RAS mutations may, therefore, help to better 
select the subgroup of patients in which it is more profit-
able to proceed to the molecular screening of these gene 
alterations.
These fusions can be identified with different meth-
ods. Classically, the detection of ALK or ROS1 has been 
performed using FISH or RT-PCR, but there is a growing 
trend in the use of mass DNA sequencing techniques, which 
has the advantage of allowing the simultaneous evaluation 
of multiple genes with potential utility as therapeutic tar-
gets. Other useful techniques include complete or directed 
sequencing of tumour RNA, sequencing of circulating DNA 
or IHC (generally used as screening).
The presence of gene rearrangements in ALK, ROS1 or 
NTRK has been associated with worse survival (15.6 versus 
33.7 months for patients with [n = 27] or without [n = 319] 
tumour gene fusions, respectively) [39]. RET fusions 
have also been associated with worse survival in a series 
of 24 positive RET patients [40]. In November 2018, the 
FDA approved the specific TRK inhibitor larotrectinib for 
the treatment of tumours with NTRK1/2/3 fusions, with 
an overall response rate of 75% (including two of three 
patients with CRC) and a median duration of response and 
PFS not attained after a median follow-up of 9.4 months 
(PFS at 1 year: 55%) [39]. This is the second tumour-agnos-
tic approval in the history of antineoplastic therapy after 
approval of pembrolizumab for MSI tumours. Entrectinib 
was approved in August 2019 for the treatment of tumours 
with NTRK fusions.
Pathological aspects
What is relevant in the pathology diagnosis of CRC?
Tumour budding (TB) and poorly differentiated clusters 
(PDC)
The most important prognostic factors in CRC according 
to the American Joint Committee on Cancer (AJCC) and 
the 8th edition of the International Union Against Can-
cer (UICC) are (i) TNM stage, (ii) venous, lymphatic or 
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perineural invasion and (iii) discontinuous tumour deposits 
[41]. The determination of TB has been incorporated into 
the pathology diagnosis protocol of the College of Ameri-
can Pathologists (CRC) v4.0.0.1 and the NCCN guidelines 
v2.2019. Other factors, such as type, histological grade, the 
configuration of the tumour border and intratumoural inflam-
matory infiltrate, influence the prognosis and treatment of 
patients. Tumour budding or TB, defined by the presence of 
isolated tumour cells and/or groups of less than five cells in 
the stroma of an invasive front of the tumour, is the morpho-
logical evidence of the epithelial-mesenchymal transition 
process and is an independent factor of poor prognosis in 
CRC. TB is relevant in different clinical contexts: (i) in pT1 
CRC as an independent predictor of lymph node metastasis, 
(ii) in stage II CRC predicts recurrence risk and contributes 
to therapeutic management [42, 43], and (iii) intratumoural 
TB in endoscopic biopsies allows the individualization of 
neoadjuvant treatment in rectal carcinomas [44, 45]. The 
International Tumour Budding Consensus Conference 
(ITBCC) agreed to count TB with HE at the area of the 
tumour front with the most density using a 20× objective 
and a field of 0.785 mm2. TB is classified as Bd1-low (0–4 
buds), Bd2-intermediate (5–9 buds) and Bd3-high (10 or 
more buds). Providing the numerical value of buds [e.g., 
Bd3 (count 17)] is recommended [46]. TB should be evalu-
ated with caution in medullary carcinomas and can be very 
difficult to count in tumours with glandular fragmentation 
with marked acute inflammation. TB must be distinguished 
from PDCs, defined as groups of five or more tumour cells 
in the invasive tumour front that do not form glandular struc-
tures [4]. TB should not be reported in rectal tumours treated 
with neoadjuvancy, or in mucinous carcinomas with signet 
ring cells within mucus lakes. If TB cannot be assessed, it 
is indicated as no non-assessable with an explanatory note 
[47, 48].
Lymph node staging
Lymph node staging (pN) is an important prognostic factor 
in CRC, a predictor of relapse and survival and determinant 
of the therapeutic management of patients. The pN stage is 
obtained from the analysis of lymph nodes stained with HE, 
which has low sensitivity for detecting lymph node micro-
metastases in stages I-II CRC. HE staining analyses less than 
1% of lymph node tissue [49–53], resulting in 11–24% false 
negatives. A meta-analysis concluded that the presence of 
micrometastases in lymph nodes undetected by HE is asso-
ciated with worse survival [54]. To improve the sensitivity 
of lymph node analysis, molecular lymph node staging has 
been performed, which has shown an improvement in pN 
staging, with respect to HE.
The OSNA technique detects copies of CK19 messen-
ger RNA (mRNA) in lymph nodes, achieving overstaging 
in 11–50% of HE-determined pN0 patients. Likewise, the 
total tumour load (TTL) or number of CK19 copies in the 
lymph nodes is correlated with classical high-risk factors 
in CRC, such as pT and pN stage, histologic grade, muci-
nous or signet ring histology, tumour size, male sex, lym-
phatic invasion and number of lymph nodes assessed [55, 
56]. Recently, TTL has been correlated with prognosis. The 
incorporation of molecular lymph node staging in CRC will 
allow to select stage II patients for adjuvant therapy and 
assist patient management.
What are the requirements of an optimal sample?
For the study of biomarkers in CRC, a sample with enough 
amount of well-preserved tumour will guarantee the perfor-
mance of the analysis and quality of the results.
Preservation of tumour material
Currently, the primary source for biomarkers studies 
are FFPE tumours and normal tissues, stored at room 
temperature.
Although the use of formaldehyde solution is the uni-
versal method of tissue fixation, formaldehyde produces 
covalent bridges in aqueous solutions and interacts with 
the -NH2 groups of proteins, forming cross-linked meth-
ylene bridges; the tertiary and quaternary conformations 
of these bridges are reversible (epitope retrieval), and they 
interact with DNA by forming hydroxy methylene bridges 
between two amino groups. In addition, treatment with for-
maldehyde can produce aberrant mutations by the forma-
tion of apurinic and apyrimidinic sites, DNA degradation 
and cross-linking of cytosines and has recently been con-
sidered carcinogenic. Therefore, alternative fixatives have 
been developed to improve the preservation of nucleic acids. 
Among these,  PAXgene® Tissue Fix (PreAnalytix GmbH 
Hombrechtikon, Switzerland) and glyoxal acid-free (GAF) 
stand out [57, 58]. The prolonged storage of paraffin blocks 
at room temperature causes the constant degradation of the 
nucleic acids regardless of the type of fixative used. To slow 
this degradation process, the blocks should be stored at 4 ºC 
or frozen [59].
Minimum sufficient quantity
It is crucial to select tumour material through macro- or 
microdissection to avoid contamination with normal tissue. 
To guarantee results, a tumour cell content 10% higher than 
normal cell content is considered optimal, thus avoiding the 
possibility of false results. Currently, with the latest genera-
tion of sequencing technologies, a threshold of 5% could be 
established.
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The ideal study sample contains the greatest possible 
number of tumour cells. Thus, it is preferable to compare 
a resected piece of CRC with the content of a diagnostic 
endoscopic biopsy or cytological material [60].
Which techniques are most appropriate 
for the determination of each biomarker?
Table 1 summarizes the most important biomarkers in CRC 
along with the recommended techniques to evaluate them 
and whether its performance is optional or mandatory.
RAS mutations
Currently available technologies for mutational analysis 
of the KRAS and NRAS genes have not been significantly 
modified compared to the last guide [61, 62], except for the 
incorporation of the mutational status of the BRAF gene 
[25], as reflected in Table 2.
A large number of laboratories continue to use molec-
ular techniques based on sequencing as confirmation 
techniques of mutations (Sanger sequencing and pyrose-
quencing) or as screening techniques based on NGS, 
where different platforms allow these determinations to 
be performed simultaneously in both clinical trials and in 
research studies as well as in the assistance activities of 
several molecular pathology laboratories in Europe [63]. 
However, the vast majority of laboratories have focused 
their activity on the use of specific assays to detect spe-
cific alterations in these genes (KRAS, NRAS and BRAF) 
using commercial kits by Conformité Européenne-In Vitro 
Diagnostic (CE-IVD) at the expense of the tests developed 
by each laboratory (laboratory developed test [LDTs]), 
whose use is limited in Spain in comparison with other 
European countries, such as Holland and Germany [64].
Notably, many of the kits used to determine 
KRAS/NRAS mutations do not determine BRAF mutations 
simultaneously; therefore, many laboratories have had to 
modify their workflows as well as combine molecular tech-
niques to analyse these mutations sequentially (e.g., first, 
KRAS gene mutations are analysed, then NRAS gene muta-
tions and finally BRAF gene mutations), which increases 
response times, sample manipulation and complexity for 
obtaining these results.
In the case of the BRAF gene, the majority of the muta-
tions focus on the valine amino acid at position 600, which 
can be affected in multiple ways (V600E/E2/K/D/R or M); 
however, given that the vast majority correspond to the p. 
V600E change, this mutation can be detected by a specific 
antibody (Clone VE1) via IHC. However, although this 
technique has shown high sensitivity and analytical speci-
ficity in different studies [65, 66], confirmation is currently 
required by a molecular technique.
In recent years, there has been an increase in the use of 
commercial point of care (POC) techniques that minimize 
and automate the process of determining gene mutations, 
significantly reducing response times, reducing the risk 
of obtaining false positives/negatives and avoiding DNA 
extraction because analyses can be performed directly with 
an FFPE sample, with minimum manipulation by the tech-
nical staff and with validated results against conventional 
Table 1  Main biomarkers used in CRC 
cfDNA cell fee DNA, FISH fluorescent in  situ hybridization, IHC immunohistochemistry, MSI microsatellite instability, NGS next-generation 
sequencing, PCR polymerase chain reaction; bPCR bridging PCR, dPCR digital PCR, qPCR quantitative PCR, RT-PCR real-time PCR, SISH 
silver in situ hybridization, WT wild type
Biomarker Technique Indication
CRC—universal
 MSI IHC and/or MSI analysis by qPCR, bPCR, NGS Required
 Immunoscore or immunodensity IHC and/or digital score Optional
CRC—localized
 MSI IHC and/or PCR and MSI analysis Required
 Immunoscore or immunodensity IHC and/or digital score Optional
CRC—advanced
 MSI IHC and/or PCR and MSI analysis Required
 Extended RAS KRAS, NRAS Required
 B-RAF V600E
V600E2/K/D/R or M
Required
Optional
 HER2 IHC / FISH / SISH Optional
 Rearrangements of: NTRK1; NTRK2; 
NTRK3
IHC and FISH, NGS, RT-PCR, NanoString® Optional in MSI, MLH1 hyper-
methylation and RAS WT
 Liquid biopsy qPCR, dPCR, NGS, cfDNA Idylla Optional for patient monitorization
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Table 2  Molecular techniques employed in CRC 
Techniques available Sensitivity (% 
mutated DNA)
Characteristics
Mutational study of isolated genes (KRAS, NRAS and BRAF)
Methods of direct sequencing
 Sanger method 25 Detects any mutation
Requires a greater amount of mutated DNA
Inexpensive
 Pyrosequencing 5–10 Commercial trial available
Requires pyrosequencer
 NGS 1–5 Commercial trial available
Requires specific equipment
Requires experience in molecular biology
 PCR-fragment analysis 1–5 Commercial trial available
Requires specific equipment
Requires experience in molecular biology
Quantitative RT-PCR
 TaqMan ® PCR 10 Only detects specific mutations
No commercial trial
Requires real-time thermocycler
 Scorpions-ARMS 1 Only detects specific mutations
Commercial trial available
Requires real-time thermocycler
Mutated allele enrichment techniques
 PNA-LNA PCR clamp 0,1–1 Only detects specific mutations
Requires non-commercial LNA probes
Requires experience in molecular biology
 COLD-PCR 0,1–1 Requires experience in molecular biology
Can be associated with sequencing and pyrosequencing techniques
 PCR–RFLP 5 Only detects mutations that generate a restriction site
Commercial trial available
 DHPLC 1 Detects any mutation
Special equipment required
Requires experience in HPLC
 HRM 1 Detects any mutation
Requires specific equipment
Requires experience in molecular biology
 PCR + hybridization 1–5 Only detects specific mutations
Commercial trial available
Requires specific equipment (in the case of hybridization in arrays or strips if there is 
a large volume)
Requires experience in molecular biology
Direct techniques for determining RAS
 Point of care 1–5 Only detects specific mutations
Requires specific equipment
Does not require experience in molecular biology
 IHQ BRAF (VE1) Only detects the mutation V600E of BRAF
Requires specific automation equipment
Does not require experience in molecular biology
MSI study
 IHQ Detects mutations in the MLH1, MHS2, MSH3 and PMS2 genes
Requires specific automation equipment
Has internal controls for each staining
 PCR + MSI analysis 1–5 Detects MSI alterations
Commercial trial available
Requires sequencing and experience in molecular biology
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techniques and NGS [67], even using DNA extracted from 
paraffin-embedded samples [68].
In the coming years, it is believed that the use of specific 
algorithms based on the use of artificial intelligence will 
increase and be used to analyse both radiological and HE 
images, which will produce RAS analyses with greater pre-
cision [69, 70].
MSI
Other indispensable markers in patients with CRC are MMR 
deficiency and the presence of MSI for identifying patients 
with Lynch syndrome with prognostic purpose and to predict 
the response to different immunotherapeutic treatments.
For this purpose, in the majority of pathology laborato-
ries, IHC analysis of the four repair genes (MLH1, MSH2, 
MSH6 and PMS2) is performed; however, because the 
encoded proteins act in tandem, different groups have pro-
posed that only IHQ determination of MLH1 and MSH2 can 
be used as a screening technique [71].
In addition, PCR techniques have been used for the detec-
tion of MSI. When developing the methodology, we began 
using a panel of microsatellites (Bethesda panel) composed 
of markers that detect single base alterations (BAT25 and 
BAT26) as well as three dinucleotide markers (D2S123, 
D5S346 and D17S250), but recently, new mononucleotide 
satellites have been incorporated, which have shown better 
prediction capabilities than those of previous dinucleotides 
[72].
Finally, both recently implemented NGS techniques and 
new POC tools allow the determination of MSI with new 
satellites included in their panels and are being validated in 
different studies [73].
Alterations in HER2
The determination of the amplification of HER2 in CRC 
has generated great interest because of its prognostic and 
predictive value of response to specific treatments because 
approximately 3% of patients have such alterations [74].
The methods of analysis are the same as those used in 
breast and gastric cancers, where IHC  (HercepTest® or 
Clone 4B5) stands out, showing great concordance with 
the gene amplification detected by FISH or in silver in situ 
hybridization (SISH) [34]. Currently, both the determina-
tion of the copy number alterations (CNAs) in a tumour by 
Table 2  (continued)
Techniques available Sensitivity (% 
mutated DNA)
Characteristics
 NGS 1–5 Available commercial trials pending validation
Requires specific equipment
Requires experience in molecular biology
HER2 amplification study
 IHQ High concordance with gene amplification in those overexpressed
Requires specific automation equipment
Has interpretation guides
 In situ hybridization 1–5 Detects amplifications in a specific way
Commercial trials available
Requires experience and fluorescence microscope (FISH)
 NGS 1–5 Available commercial trials pending validation
Requires specific equipment
Requires experience in molecular biology
NTRK rearrangements study
 IHQ Overexpression associated with the presence of rearrangements of any of the three 
genes (NTRK1, NTRK2 and NRTK3)
Requires specific automation equipment
Confirmation with additional molecular techniques
 In situ hybridization 1–5 Detects amplifications in a specific way
Commercial trials available
Requires experience and fluorescence microscope (FISH) and the use of three probes
 NGS 1–5 Available commercial trials pending validation
Requires specific equipment
Requires experience in molecular biology
ARMS mutation system refractory to amplification, COLD-PCR coamplification at lower denaturation temperatures, DHPLC denaturing high-
performance liquid chromatography, FISH fluorescent in situ hybridization, HPLC high-performance liquid chromatography, HRM high-resolu-
tion fusion, IHC immunohistochemistry, MSI microsatellite instability, NGS next-generation sequencing, PCR polymerase chain reaction, PNA-
LNA peptide nucleic acid-blocked nucleic acid, RFLP restriction fragment length polymorphisms, RT-PCR real-time PCR
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NGS techniques and the quantification of the levels of HER2 
mRNA are being validated in different studies before their 
implementation in routine healthcare [39].
NTRK rearrangements
The rearrangements of the NTRK1, NTRK2 and NTRK3 
genes are of special relevance in CRC because, although 
their prevalence is very low (1.5%) [39], these alterations 
are associated with the presence of MSI, hypermethylated 
MLH1 and native RAS [75]. In addition, it is important to 
mention that they have a great predictive value of response 
to TRK inhibitors. The classical techniques for the detection 
of NTRK alterations are generally performed by IHC with 
pan-TRK clones as screening, with subsequent confirmation 
by different tests (FISH, NGS, RT-PCR or NanoString®); 
however, each one has its limitations [76].
What is the current and future role of NGS 
in CRC?
The implementation of NGS in the study of CRC will allow, 
in the future, the diagnosis of Lynch syndrome through the 
mutational study of the MMR and EPCAM genes [77] and 
will guide treatment by detecting the mutations of the main 
genes involved in the pathways of CRC carcinogenesis, such 
as RAS and BRAF, as well as the genes associated with tar-
geted treatment, such as HER2. In addition, it will be possi-
ble to classify CRC into molecular subtypes (CMS1, CMS2, 
CMS3 and CMS4) with different biological behaviours and 
therapeutic responses, which will open the possibility of 
designing personalized treatment [9]. Likewise, NGS will 
allow the identification of the tumour hypermutation status, 
which will guarantee the efficacy of immunotherapy [78].
Furthermore, through the study of ctDNA, it will be pos-
sible to monitor response to treatment, anticipate the appear-
ance of local recurrence and metastasis, and detect resistance 
to ongoing treatment [79].
Finally, the possibility of implementing the combination 
of different molecular tools in the diagnostic routine will 
also improve the quality of tumour samples [68], without 
forgetting that IHC continues to be an indispensable diag-
nostic technique [80].
What are the current and future roles 
of liquid biopsy in CRC?
A liquid biopsy is based on the analysis of a biological liq-
uid, usually blood, but also cerebrospinal fluid or urine, to 
reveal characteristics of a cancer, such as circulating tumour 
cells (CTCs), free nucleic acids (DNA or RNA), exosomes 
or tumour-derived platelets. The quantification of CTCs in 
peripheral blood has been shown to have prognostic value 
with a threshold level above or below three cells. The pos-
sibility of extracting DNA from these cells for NGS has been 
recently evaluated [81].
The most developed option in liquid biopsy is the study 
of ctDNA in peripheral blood. The biomarker with the great-
est impact on CRC is the mutation in the RAS oncogene, 
including KRAS and NRAS, in exons 2, 3 and 4, which indi-
cates patients who may be candidates for treatment with 
anti-EGFR antibodies in case of the native or non-mutated 
sequence. This technique has been studied using tumour tis-
sue as a comparison. Different publications have confirmed 
that using high sensitivity molecular techniques [82], the 
concordance between the analyses performed on tumour tis-
sue and peripheral blood exceeds 90% [83]. Correctly select-
ing the analysis technique is critical. Liquid biopsy has two 
very significant advantages compared to tissue biopsy: (i) 
it indicates the heterogeneity of the tumour and (ii) it is a 
real-time reflection of the molecular profile, which allows 
determining the dynamic evolution of the tumour.
Several studies have observed the convenience of using 
liquid biopsy in the early determination of response in 
patients with RAS mutations, in whom during the course 
of treatment the basal mutation was not detected, and in 
patients with a RAS native sequence, in whom during treat-
ment a RAS mutation is detected, predicting, presumably, 
the onset of radiological progression of the disease. The 
determination of BRAF mutations can be another important 
application of liquid biopsy because it allows monitoring 
patients with CRC with this alteration [84].
Recent research has opened the way to new uses of liq-
uid biopsy. Some studies have proposed its possible use 
for the early diagnosis of CRC; however, this option is still 
very preliminary and, for the moment, lacks an adequate 
cost-effectiveness relationship as a population screening 
technique [85]. Finally, the identification of low-incidence 
molecular alterations in CRC, such as the presence of HER2 
amplification or fusions that affect NTRK, could be evaluated 
via ctDNA by mass sequencing platforms [86].
Conclusions
In recent decades, significant progress has been made in 
understanding the molecular characteristics of CRC and in 
the identification of specific mutations that have allowed the 
development of new prognostic and predictive biomarkers in 
the different stages of the disease. These advances, together 
with those achieved through pathological knowledge, have 
justified a new edition of this guide.
With respect to the susceptibility markers of hereditary 
CRC, this panel recommends the analysis of MSI and/
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or IHC in all patients diagnosed with CRC. In addition, 
the germinal study of MMR genes should continue in 
patients with MSI and/or loss of repair protein expres-
sion. In localized stages, the determination of MSI as a 
prognostic marker is required, especially in stage II CRC. 
The standardized implementation of genomic platforms 
is not recommended due to the lack of predictive value of 
response to chemotherapy.
In patients with advanced CRC, it is essential to deter-
mine extended RAS mutations, the BRAF V600E mutation 
and the MSI status, which is usually performed via IHC 
for MLH1, MSH2, MSH6 and PMS2. The determination 
of extended RAS mutations is mandatory before mak-
ing therapeutic decisions (I-A). The RAS analysis should 
include HRAS, KRAS and NRAS, exons 2 (codons 12 and 
13), 3 (codons 59 and 61) and 4, as negative predictive fac-
tors of the anti-EGFR response. The BRAF V600E muta-
tion is required due to its recognized negative prognostic 
value (I-A) and, recently, as a predictive marker of specific 
biological treatments (cetuximab, encorafenib and bini-
metinib). The determination of MSI acquires predictive 
value in advanced CRC for immunotherapy treatment with 
pembrolizumab or nivolumab (II-B).
Another recommended marker in advanced CRC is the 
amplification of HER2 as a negative predictive marker of 
anti-EGFR response and as a response marker for dual anti-
HER2 therapy. Its determination is recommended, at least in 
native RAS tumours resistant to anti-EGFR. The ALK, ROS1 
and NTRK fusions, despite their low incidence, have clinical 
interest due to recent approval for specific treatments.
The greatest contribution to the genetic study of CRC 
will come from liquid biopsies, with which minimal residual 
disease can be detected after surgery. This technique reflects 
tumour heterogeneity and molecular profiles in real time, 
reporting the dynamic evolution of the tumour. The imple-
mentation of NGS will improve genotypic knowledge, the 
tumour hypermutation status and molecular subtypes. The 
combination of different molecular tools in the diagnostic 
routine will improve the diagnosis using and quality of 
tumour samples.
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